SOURCE: AtheroNova Inc.

AtheroNova Inc.

May 03, 2011 10:36 ET

AtheroNova to Address Significant Unmet Need in Stroke Prevention With Atherosclerotic Plaque Regression Compound to Treat ICAD

Accumulating Evidence Suggests That ICAD May Also Contribute to the Development of Cognitive Impairment and Alzheimer's Disease

IRVINE, CA--(Marketwire - May 3, 2011) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, will pursue an additional indication to address significant unmet needs in stroke prevention with a compound to treat Intracranial atherosclerosis disease (ICAD), regarded as a primary cause of ischemic stroke.

Following an extensive review of the Company's proprietary anti-plaque compounds, published data on statistical disease trends, and ongoing research, AtheroNova's Scientific Advisory Board (SAB) has recommended the pursuit of an additional indication for the treatment and prevention of intracranial atherosclerosis disease.

Multiple studies have identified ICAD as a major public health problem, probably the major cause of stroke, and a main cause of long-term disability and mortality in the United States and throughout the world. Over 700,000 patients a year suffer a stroke in the United States with total costs exceeding $42 Billion. Recent studies have found ICAD to be widespread, with prevalence rising 3 to 5 times that of the general population in patients with subclinical undiagnosed atherosclerosis affecting other parts of the body including carotid, coronary or peripheral artery disease. There has been no medical consensus on best treatment for symptomatic ICAD, and no approved medications for the reduction of intracranial atherosclerotic plaques in any form of the disease.

ICAD has been reported to be a dynamic and aggressive disease with symptomatic patients exhibiting particularly high rates of recurrent strokes. Accumulating evidence also suggests that ICAD also contributes to the development of cognitive impairment and Alzheimer's disease. One particular form of dementia, identified as "vascular dementia" has been linked to ICAD and represents approximately 20% of all cases of dementia with an estimated patient population of 1.7 million Americans in 2011. Additional 2011 data indicates over 5.4 million Americans are living with Alzheimer's and project a patient population of as many as 16 million by 2050. Total costs of care in 2011 are expected to exceed $153 billion, an increase of $11 billion over the prior year.

"Atherosclerotic plaque is the primary cause of coronary artery disease, but a rapidly growing body of evidence makes clear the atherosclerotic plaque is also a major cause of stroke and may play a role in the development of Alzheimer's disease, cognitive impairment and dementia," stated Thomas W. Gardner, CEO of AtheroNova. "The treatment of atherosclerosis as it applies to coronary disease presents a huge market opportunity. With an aging population and the lack of effective preventative treatments for ischemic stroke and Alzheimer's, the potential of our compounds to address the urgent unmet needs in these markets will allow us to address an additional rapidly growing market and will be an important part of our development program as we Prepare for Investigational New Drug (IND) filing expected later this year."

AtheroNova is currently conducting two second round pre-clinical studies evaluating the atherosclerotic plaque regression efficacy of the Company's compounds at two major research centers. Following the completion of the second round pre-clinical program expected during the third quarter of this year, the Company plans to continue the development program with an IND application for plaque regression compounds for the treatment of atheroslerosis.

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the preclinical trials being conducted for the Company, the expected time to completion of the research and the ongoing development for AtheroNova's plaque regression compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Company Contact:

    Thomas Gardner
    Chief Executive Officer
    (949) 476-1100

    Mark Selawski
    Chief Financial Officer
    (949) 476-1100

    Investor Contact:

    Leon Hamerling
    Investor Media Group
    (877) 725-2500